NASDAQ:TRAW Traws Pharma (TRAW) Stock Price, News & Analysis $2.30 -0.10 (-4.17%) Closing price 03/31/2025 04:00 PM EasternExtended Trading$2.30 0.00 (-0.04%) As of 03/31/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Traws Pharma Stock (NASDAQ:TRAW) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Traws Pharma alerts:Sign Up Key Stats Today's Range$2.26▼$2.6950-Day Range$2.29▼$8.2952-Week Range$2.02▼$24.75Volume44,519 shsAverage Volume155,928 shsMarket Capitalization$8.40 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewTraws Pharma, Inc., a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza. It is also developing narazaciclib, a multi-kinase CDK4/6 inhibitor, which is in Phase 1/2 clinical trials in patients with cancer, with or without co-administration of letrozole to define the recommended phase 2 dose for further development in endometrial cancer; and oral rigosertib, which is administered alone or in combination for investigation in various cancers. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.Read More… Remove Ads Traws Pharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks24th Percentile Overall ScoreTRAW MarketRank™: Traws Pharma scored higher than 24% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Traws Pharma. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Traws Pharma is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Traws Pharma is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTraws Pharma has a P/B Ratio of 0.18. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Traws Pharma's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.08% of the float of Traws Pharma has been sold short.Short Interest Ratio / Days to CoverTraws Pharma has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Traws Pharma has recently decreased by 55.72%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTraws Pharma does not currently pay a dividend.Dividend GrowthTraws Pharma does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted2.08% of the float of Traws Pharma has been sold short.Short Interest Ratio / Days to CoverTraws Pharma has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Traws Pharma has recently decreased by 55.72%, indicating that investor sentiment is improving significantly. News and Social Media2.4 / 5News Sentiment0.34 News SentimentTraws Pharma has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.80 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 17 news articles for Traws Pharma this week, compared to 2 articles on an average week.MarketBeat Follows2 people have added Traws Pharma to their MarketBeat watchlist in the last 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Traws Pharma insiders have not sold or bought any company stock.Percentage Held by Insiders13.60% of the stock of Traws Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 7.95% of the stock of Traws Pharma is held by institutions.Read more about Traws Pharma's insider trading history. Receive TRAW Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Traws Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address TRAW Stock News HeadlinesTraws Pharma, Inc.: Traws Pharma Reports Full Year 2024 Results and Business HighlightsMarch 31 at 8:36 PM | finanznachrichten.deTraws Pharma Reports Full Year 2024 Results and Business HighlightsMarch 31 at 10:34 AM | markets.businessinsider.comTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’s secret plan to trigger the greatest transfer of wealth since FDR and LBJ – trillions of dollars could be redistributed.April 1, 2025 | Porter & Company (Ad)Traws Pharma (TRAW) to Release Quarterly Earnings on MondayMarch 31 at 1:26 AM | americanbankingnews.comTraws Pharma Announces CEO Transition as Werner Cautreels RetiresMarch 30 at 7:42 AM | msn.comTraws Pharma, Inc.: Traws Pharma Announces Management UpdatesMarch 29 at 6:40 AM | finanznachrichten.deTraws Pharma: Werner Cautreels to Retire as CEO, While Continuing as a Bd Member >TRAWMarch 29 at 1:37 AM | marketwatch.comTraws Pharma: Werner Cautreels to Retire as CEO, While Continuing as a Bd Member >TRAWMarch 29 at 1:37 AM | marketwatch.comSee More Headlines TRAW Stock Analysis - Frequently Asked Questions How have TRAW shares performed this year? Traws Pharma's stock was trading at $8.88 at the beginning of 2025. Since then, TRAW shares have decreased by 74.1% and is now trading at $2.30. View the best growth stocks for 2025 here. How were Traws Pharma's earnings last quarter? Traws Pharma, Inc. (NASDAQ:TRAW) issued its quarterly earnings data on Monday, March, 31st. The company reported $95.66 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($7.00) by $102.66. How do I buy shares of Traws Pharma? Shares of TRAW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Traws Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Traws Pharma investors own include Clearside Biomedical (CLSD), Evofem Biosciences (EVFM), Nikola (NKLA), Palatin Technologies (PTN), Sirius XM (SIRI), Adverum Biotechnologies (ADVM) and Aptinyx (APTX). Company Calendar Today3/31/2025Last Earnings3/31/2025Next Earnings (Estimated)4/07/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:TRAW Previous SymbolNASDAQ:TRAW CIK1130598 Webwww.onconova.com Phone267-759-3680Fax267-759-3681Employees17Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($141.56) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-18,950,000.00 Net Margins-62,294.25% Pretax Margin-62,294.25% Return on EquityN/A Return on Assets-822.38% Debt Debt-to-Equity RatioN/A Current Ratio1.07 Quick Ratio1.07 Sales & Book Value Annual Sales$226,000.00 Price / Sales37.16 Cash FlowN/A Price / Cash FlowN/A Book Value$12.70 per share Price / Book0.18Miscellaneous Outstanding Shares3,651,000Free Float3,154,000Market Cap$8.40 million OptionableOptionable Beta1.42 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report This page (NASDAQ:TRAW) was last updated on 4/1/2025 by MarketBeat.com Staff From Our PartnersNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredRetirement Nightmare? It’s Already Happening.The market is on edge. Every day, another company slashes its dividend, leaving investors scrambling. Intel...Investors Alley | SponsoredNew “Trump” currency proposed in DCA former U.S. Presidential Advisor has come forward with a stern warning to investors: “Get out of tech, no...Paradigm Press | SponsoredLive Footage From Elon Musk’s “Area 51”What’s happening inside this nondescript building in South Memphis is so incredible… That Elon’s competitor...Brownstone Research | SponsoredTermination: 18F (read immediately)Have you ever heard of the government's 18F program? It helped manage digital services across the governmen...Altimetry | Sponsored10X Bigger than AI, quantum, EVs, crypto, and robotics combined?World Economic Forum: "Arguably the Most Exciting Human Discovery Since Fire" Sam Altman, Bill Gates, and M...Stansberry Research | Sponsored“Massive Financial Reset Is Coming”The U.S. markets will see a massive reset, beginning days from now. But the "reset" isn't what you might ex...InvestorPlace | SponsoredGold Hits $3,000… Here’s How You Can Get More for Under $20With gold surging to record highs, currently trading above $3,000 an ounce, and central banks aggressively sto...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Traws Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Traws Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.